[go: up one dir, main page]

AR133035A1 - Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) - Google Patents

Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr)

Info

Publication number
AR133035A1
AR133035A1 ARP240101597A ARP240101597A AR133035A1 AR 133035 A1 AR133035 A1 AR 133035A1 AR P240101597 A ARP240101597 A AR P240101597A AR P240101597 A ARP240101597 A AR P240101597A AR 133035 A1 AR133035 A1 AR 133035A1
Authority
AR
Argentina
Prior art keywords
hmgcr
dsrna
antisense strand
strand
expression
Prior art date
Application number
ARP240101597A
Other languages
English (en)
Inventor
Dongxu Shu
Pengcheng Patrick Shao
Shiwei Xia
Original Assignee
Shanghai Argo Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Argo Biopharmaceutical Co Ltd filed Critical Shanghai Argo Biopharmaceutical Co Ltd
Publication of AR133035A1 publication Critical patent/AR133035A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/343Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/11Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan composiciones y métodos útiles para reducir la expresión del gen de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR) y para el tratamiento de enfermedades y afecciones asociadas a HMGCR. Se proporcionan agentes de ARNbc de HMGCR, agentes polinucleotídicos antisentido de HMGCR, composiciones que comprenden agentes de ARNbc de HMGCR y composiciones que comprenden agentes polinucleotídicos antisentido de HMGCR que pueden usarse para reducir la expresión de HMGCR en células y sujetos. Reivindicación 1: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc que incluye una cadena sentido y una cadena antisentido, en donde la cadena sentido comprende al menos 15 nucleótidos contiguos que difieren en no más de 3 nucleótidos de la secuencia de nucleótidos de la SEQ ID Nº 1 y la cadena antisentido comprende al menos 15 nucleótidos contiguos que difieren en no más de 3 nucleótidos de la secuencia de nucleótidos de la SEQ ID Nº 2, en donde la cadena sentido y la cadena antisentido pueden ser parcial, sustancial o totalmente complementarias entre sí. Reivindicación 4: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc comprende una cadena sentido y una cadena antisentido, comprendiendo las posiciones de nucleótidos 2 a 18 en la cadena antisentido una región de complementariedad a un transcrito de ARN de HMGCR, en donde la región de complementariedad comprende al menos 15 nucleótidos contiguos que difieren en 0, 1, 2 o 3 nucleótidos de una de las secuencias antisentido enumeradas en una de las Tablas 1 - 3, y comprendiendo opcionalmente un ligando de direccionamiento. Reivindicación 6: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc incluye una cadena sentido y una cadena antisentido, en donde la cadena antisentido de ARNbc es sustancialmente o totalmente complementaria a una cualquiera de una región diana de la SEQ ID Nº 1, y preferentemente el agente de ARNbc comprende una secuencia de cadena antisentido expuesta en una cualquiera de las Tablas 1 - 3. Reivindicación 11: Un agente de ácido ribonucleico bicatenario (ARNbc) para inhibir la expresión de la 3-hidroxi-3-metilglutaril-CoA reductasa (HMGCR), en donde el agente de ARNbc incluye una cadena sentido y una cadena antisentido, en donde la cadena sentido es complementaria a la cadena antisentido, en donde la cadena antisentido comprende una región complementaria a parte de un ARNm que codifica HMGCR, en donde cada cadena tiene de aproximadamente 15 a aproximadamente 30 nucleótidos de longitud, en donde la secuencia de cadena sentido puede representarse por la fórmula (1): 5’-(N’L)ₙ’ N’LN’L N’N₁ N’N₂ N’N₃ N’N₄ N’L N’F N’L N’N₅ N’N₆ N’L N’L N’L (N’L)ₘ’-3’ (1) en donde: cada N’F representa un nucleótido modificado con 2’-fluoro; cada N’N₁, N’N₂, N’N₃, N’N₄, N’N₅ y N’N₆ representa independientemente un nucleótido modificado o sin modificar; cada N’L representa independientemente un nucleótido modificado o sin modificar, pero no un nucleótido modificado con 2’-fluoro; y m’ y n’ son cada uno independientemente un número entero de 0 a 7. Reivindicación 39: Una composición que comprende un agente de ARNbc de una cualquiera de las reivindicaciones 1 - 38. Reivindicación 44: Una célula que comprende un agente de ARNbc de una cualquiera de las reivindicaciones 1 - 38, opcionalmente, la célula es una célula de mamífero, opcionalmente una célula humana.
ARP240101597A 2023-06-21 2024-06-21 Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) AR133035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023101548 2023-06-21

Publications (1)

Publication Number Publication Date
AR133035A1 true AR133035A1 (es) 2025-08-20

Family

ID=93934852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101597A AR133035A1 (es) 2023-06-21 2024-06-21 Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr)

Country Status (4)

Country Link
AR (1) AR133035A1 (es)
TW (1) TW202500747A (es)
UY (1) UY40801A (es)
WO (1) WO2024260434A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US20040006031A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of HMG-CoA reductase expression
FR2840217B1 (fr) * 2002-06-03 2005-06-24 Oreal Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
EP3604537B1 (en) * 2003-06-13 2021-12-08 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
MX2007007283A (es) * 2007-06-15 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal.
WO2023009687A1 (en) * 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof

Also Published As

Publication number Publication date
UY40801A (es) 2024-12-13
WO2024260434A1 (en) 2024-12-26
TW202500747A (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
AU778474B2 (en) Method and medicament for inhibiting the expression of a defined gene
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
WO2006073601A3 (en) Methods and compositions for rna interference
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
BR112022014513A2 (pt) Agentes caotrópicos para reduzir a formação de rna de fita dupla
RU2011124146A (ru) Композиции и способы подавления экспрессии генов фактора vii
AR123420A1 (es) Inhibidores de dux4 y métodos de uso de estos
US10612020B2 (en) Artificial mimic miRNA for controlling gene expression, and use of same
JP2022078058A (ja) ゲノム編集方法
Brinkman et al. Nucleoside analogs in ADAR guide strands targeting 5′-UA [combining low line] sites
MX2025010451A (es) Composiciones y métodos para la inhibición de la expresión de genes de la subunidad beta e de la inhibina (inhbe)
Yu et al. Comprehensive analysis of miRNA profiles reveals the role of Schistosoma japonicum miRNAs at different developmental stages
AR133035A1 (es) Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr)
Wang et al. Testis brain ribonucleic acid-binding protein/translin possesses both single-stranded and double-stranded ribonuclease activities
MX2025006656A (es) Oligonucleotidos antisentido para el tratamiento de enfermedades cardiovasculares
WO2021202443A3 (en) Compositions and methods for silencing dnajc15 gene expression
Kang et al. Optimization of double‐stranded RNAi intrathoracic injection method in Aedes aegypti
WO2024211376A3 (en) Compositions and methods for treating cag repeat diseases
AR131145A1 (es) Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
US20140066595A1 (en) Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom
KR101181728B1 (ko) 세포 내 rpS3 발현 억제 siRNA
KR20210120034A (ko) 사람 세포내 부착 분자 1(icam-1)에 대한 안티센스 약물
CN102965371A (zh) 一种抑制BMP15基因表达的siRNA 及其应用
Priyadarshini et al. Downregulation of ribosomal RNA (rRNA) genes in human head and neck squamous cell carcinoma (HNSCC) cells is linked to rDNA promoter hypermethylation
AR126265A1 (es) Composiciones y métodos para silenciar la expresión de myoc